14046678
| Pregunta | Respuesta |
| Therapeutic class | Anticoagulant |
| Pharmaceutical class | Low molecular weight heparin |
| Indications | - Prevention of VTE in surgical or bed-bound med patients - treatment for DVT and PE - Treatment of acute STEMI and non-STEMI as well as unstable angina |
| Action | Inactivates clotting factors thrombonin and Xa by binding to antithrombonin III |
| Absorption | Well-absorbed subcut |
| Distribution | Does not cross the placenta or enter breast milk |
| Metabolism & excretion | Metabolised by the liver and excreted by the kidneys in urine |
| Half-life | 4.5 hrs |
| Contraindications/precautions | - caution in renally impaired - Hepatic impairment - Elderly may require dose adjustment - Those at risk of bleeding |
| Adverse reactions | CVS: brusing and bleeding CNS: pain at the inject. site May cause hyperkalemia, HAEMO: can cause irreversible thrombocytopenia |
| Interactions | When used in conjunction with other anticoagulants can increase potency |
| Nursing assessment implications | - Liver & renal function - Electrolyte balance - Post administration clotting factor blood tests |
| Education | Ask patient to advise if they notice any unexplained bleeding or bruising May require self-admin education if prolonged post-discharge use is required |
¿Quieres crear tus propias Fichas gratiscon GoConqr? Más información.